Drugs & Targets FDA expands Reblozyl’s indication to first-line treatment of anemia in lower-risk myelodysplastic syndromes September 08, 2023Vol.49 No.33
Drugs & Targets FDA clears AION’s continuous temperature monitoring device and software platform September 08, 2023Vol.49 No.33
Drugs & TargetsFree FDA grants accelerated approval to Talvey for R/R multiple myeloma August 11, 2023Vol.49 No.32
Drugs & TargetsFree FDA approves companion diagnostic to Ayvakit in gastrointestinal stromal tumors August 11, 2023Vol.49 No.32
Drugs & Targets FDA approves Jemperli with chemotherapy for endometrial cancer August 04, 2023Vol.49 No.31
Drugs & Targets FDA approves Lonsurf with bevacizumab for previously treated metastatic colorectal cancer August 04, 2023Vol.49 No.31
In Brief Patient Engagement Collaborative calls for applications for members July 21, 2023Vol.49 No.29
